Best Pharmaceutical Mass Flow Controller Market Tips You Will Read

The mass flow controller (MFC) is used in the production of an active pharmaceutical ingredient through chemical synthesis. The rise in the demand for active pharmaceutical ingredients due to the increase in the prevalence of the disease across the world is driving the growth of the market in the forecast period. Pharmaceutical companies have many precise, important steps they must follow to create their products. This process works to their advantage by effectively creating more areas for control. There are a wide variety of options that help them to measure most efficiently.  Pharmaceutical manufacturing occurs in two general steps. In the first step, manufacturers convert raw materials into APIs. The second step involves creating the final formulation by mixing APIs and excipients into tablets, capsules, solutions, etc., and finally packaging the drug for the end users. The mass flow controller (MFC) can play an important role in pharmaceutical manufacturing. The global demand for APIs is currently exhibiting strong growth. One of the major drivers of this market is the rising number of blockbuster patent expiries creating a significant opportunity for generic APIs. Moreover, there has been a strong demand for APIs for biologicals.

The launches of new drugs and biological products, acquisitions, collaborations, and regional expansions are some of the strategic initiatives to maintain stability in the market. This is likely to fuel market growth shortly. Countries such as India are being preferred over China for the export of API owing to geopolitical situations and the demand to reduce dependence on China for API products. Furthermore, governments of many countries have formulated plans and granted incentives to promote the production of API. Thus, the growing production of API in the developing countries of Asia pacific has created a surge in the demand for mass flow controllers (MFC) in the region. The global geriatric population is rising. According to the UN, in 2017, the population aged 65 and above is anticipated to increase from 962 million in 2017 to 2.1 billion by 2050. Aging weakens the immune system and increases a patient’s susceptibility to acquiring infectious diseases. Moreover, impairment in body functions enhances the chances of getting other diseases, such as CVD and diabetes. In addition, pharmaceutical companies benefit from API production outsourcing as it eradicates the need for expensive manufacturing unit installation and labor force. These factors are driving the market growth in the forecast period.

North America is expected to hold the largest share of about 38.65% in the global pharmaceutical mass flow controller market in 2019, owing to the increasing implementation of these controllers in pharmaceutical industries. 

North American pharmaceutical mass flow controller and is estimated to grow at a CAGR of XX% during the forecast period (2022-2029) to reach a market value of USD XX million by 2029. As of 2019, there are more than 800 active Investigational New Drugs (IND) waiting for approval by the FDA. These burgeoning approvals and drug-developing pipelines are expected to promise more opportunities to the market. Apart from this, the US Government has increased the overall healthcare expenditure propelling the market growth. Pharmaceutical manufacturers have increased their investments in R&D for the development of better-quality mass flow controllers since it has a direct effect on the safety and efficacy of the drug.  For instance, ventilation devices used during emergency treatment are required for providing an optimum flow of oxygen to the ailing patient. In this case, the performance capability of mass flow controllers is crucial. The United States healthcare spending is expected to have a 0.8% faster growth than the gross domestic product (GDP) per year over the 2018-27 period. The health share of GDP would rise from 17.9% in 2017 to 19.4% by 2027, as per estimates from the Centers for Medicare & Medicaid Services. The stricter regulation in the country ensures superior quality of the manufacturing and the end-product that is being adhered to by the CMOS.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com